Advertisement

Drug Safety

pp 1–12 | Cite as

Long-Term Safety and Efficacy of Fecal Microbiota Transplant in Active Ulcerative Colitis

  • Xiao Ding
  • Qianqian Li
  • Pan Li
  • Ting Zhang
  • Bota Cui
  • Guozhong Ji
  • Xiang LuEmail author
  • Faming ZhangEmail author
Short Communication

Abstract

Introduction and objective

The therapeutic role of fecal microbiota transplantation in ulcerative colitis varies across different reports. This study aims to evaluate the long-term safety and efficacy of a strategy called step-up fecal microbiota transplantation for ulcerative colitis.

Methods

Two clinical trials (NCT01790061, NCT02560727) for moderate-to-severe ulcerative colitis (Mayo score range 6–12) were performed from November 2012 to July 2017. Both studies were pooled for analysis on the safety and efficacy of fecal microbiota transplantation in patients with ulcerative colitis over a 1-year follow-up. The step-up fecal microbiota transplantation strategy included step 1: single fecal microbiota transplantation; step 2: two or more fecal microbiota transplantations; and step 3: fecal microbiota transplantations followed by immunosuppressants. Long-term clinical efficacy and adverse events were assessed, and multiple factors related to fecal microbiota transplantation were evaluated.

Results

Of 134 eligible patients in this real-word study, 81.3% (109/134) were included for analysis. The follow-up ranged from 1 to 5 years. Fecal microbiota transplantation-related adverse events were observed in 17.4% (43/247) of fecal microbiota transplantation procedures including one serious adverse event (myasthenia gravis) and 56 non-serious adverse events. Multivariable logistic regression analysis showed that both the method of preparation of microbiota from stool using the automatic system and the delivery method of colonic transendoscopic enteral tubing were associated with a lower rate of fecal microbiota transplantation-related adverse events (p = 0.023, p = 0.017, respectively). In total, 74.3% (81/109) and 51.4% (56/109) of patients achieved clinical response at 1 month and 3 months after step-up fecal microbiota transplantation, respectively.

Conclusions

Fecal microbiota transplantation should be a safe and promising therapy for ulcerative colitis. The improved fecal microbiota preparation and colonic transendoscopic enteral tubing might reduce the rate of adverse events in ulcerative colitis.

Trial registration

ClinicalTrials.gov NCT01790061, NCT02560727.

Notes

Acknowledgements

The authors thank the following investigators who participated in this study: Jun Wang (Institute of Microbiology, Chinese Academy of Science), Yongzhan Nie (The Fourth Military Medical University), Kaichun Wu (The Fourth Military Medical University), and Daiming Fan (The Fourth Military Medical University). The authors also thank Dr. Heena Buch for her kind assistance with language improvement.

Author contributions

FZ and XL designed the study and edited the manuscript. XD, QL, BC, PL, TZ, GJ, and FZ were responsible for the recruitment and treatment of the patients. QL and XD participated in the data analysis and wrote the manuscript. All authors read and approved the final manuscript.

Compliance with Ethical Standards

Funding

This study was funded by the publicly donated Intestine Initiative Foundation; Jiangsu Province Creation Team and Leading Talents Project (Zhang F); National Natural Science Foundation of China (81670495, 81600417); Top-Notch Talent Research Projects (LGY2017080); Project of National Health and Family Planning Commission (201502026); and the National Clinical Research Center for Digestive Diseases, Xi’an, China (2015BAI13B07).

Conflict of interest

Faming Zhang invented the concept of GenFMTer and transendoscopic enteral tubing and related devices. Xiao Ding, Qianqian Li, Pan Li, Ting Zhang, Bota Cui, Guozhong Ji, and Xiang Lu have no conflicts of interest that are directly relevant to the content of this study.

Ethics approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. This study was reviewed and approved by the Second Affiliated Hospital of the Nanjing Medical University Institutional Ethical Review Board.

Consent to participate

Informed consent was obtained from all individual participants included in the study.

Supplementary material

40264_2019_809_MOESM1_ESM.pdf (210 kb)
Supplementary material 1 (PDF 209 kb)
40264_2019_809_MOESM2_ESM.pdf (17 kb)
Supplementary material 2 (PDF 16 kb)

References

  1. 1.
    Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology. 2014;146(6):1489–99.CrossRefGoogle Scholar
  2. 2.
    Shanahan F, Quigley EM. Manipulation of the microbiota for treatment of IBS and IBD: challenges and controversies. Gastroenterology. 2014;146(6):1554–63.CrossRefGoogle Scholar
  3. 3.
    Zhang F, Luo W, Shi Y, Fan Z, Ji G. Should we standardize the 1,700-year-old fecal microbiota transplantation? Am J Gastroenterol. 2012;107(11):1755 (author reply 1756).CrossRefGoogle Scholar
  4. 4.
    Borody TJ, Brandt LJ, Paramsothy S. Therapeutic faecal microbiota transplantation: current status and future developments. Curr Opin Gastroenterol. 2014;30(1):97–105.CrossRefGoogle Scholar
  5. 5.
    Bennet JD, Brinkman M. Treatment of ulcerative colitis by implantation of normal colonic flora. Lancet. 1989;1(8630):164.CrossRefGoogle Scholar
  6. 6.
    Kunde S, Pham A, Bonczyk S, Crumb T, Duba M, Conrad H Jr, et al. Safety, tolerability, and clinical response after fecal transplantation in children and young adults with ulcerative colitis. J Pediatr Gastroenterol Nutr. 2013;56(6):597–601.CrossRefGoogle Scholar
  7. 7.
    Moayyedi P, Surette MG, Kim PT, Libertucci J, Wolfe M, Onischi C, et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology. 2015;149(1):102-9.e6.CrossRefGoogle Scholar
  8. 8.
    Rossen NG, Fuentes S, van der Spek MJ, Tijssen JG, Hartman JH, Duflou A, et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology. 2015;149(1):110-8.e4.CrossRefGoogle Scholar
  9. 9.
    Paramsothy S, Kamm MA, Kaakoush NO, Walsh AJ, van den Bogaerde J, Samuel D, et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet. 2017;389(10075):1218–28.CrossRefGoogle Scholar
  10. 10.
    Vermeire S, Joossens M, Verbeke K, Wang J, Machiels K, Sabino J, et al. Donor species richness determines faecal microbiota transplantation success in inflammatory bowel disease. J Crohns Colitis. 2016;10(4):387–94.CrossRefGoogle Scholar
  11. 11.
    Ott SJ, Waetzig GH, Rehman A, Moltzau-Anderson J, Bharti R, Grasis JA, et al. Efficacy of sterile fecal filtrate transfer for treating patients with Clostridium difficile infection. Gastroenterology. 2017;152(4):799-811.e7.CrossRefGoogle Scholar
  12. 12.
    Cui B, Feng Q, Wang H, Wang M, Peng Z, Li P, et al. Fecal microbiota transplantation through mid-gut for refractory Crohn’s disease: safety, feasibility, and efficacy trial results. J Gastroenterol Hepatol. 2015;30(1):51–8.CrossRefGoogle Scholar
  13. 13.
    Cui B, Li P, Xu L, Zhao Y, Wang H, Peng Z, et al. Step-up fecal microbiota transplantation strategy: a pilot study for steroid-dependent ulcerative colitis. J Transl Med. 2015;13:298.CrossRefGoogle Scholar
  14. 14.
    Zhang FM, Wang HG, Wang M, Cui BT, Fan ZN, Ji GZ. Fecal microbiota transplantation for severe enterocolonic fistulizing Crohn’s disease. World J Gastroenterol. 2013;19(41):7213–6.CrossRefGoogle Scholar
  15. 15.
    Zhang F, Cui B, He X, Nie Y, Wu K, Fan D, et al. Microbiota transplantation: concept, methodology and strategy for its modernization. Protein Cell. 2018;9(5):462–73.CrossRefGoogle Scholar
  16. 16.
    Stewart CJ, Ajami NJ, O’Brien JL, Hutchinson DS, Smith DP, Wong MC, et al. Temporal development of the gut microbiome in early childhood from the TEDDY study. Nature. 2018;562(7728):583–8.CrossRefGoogle Scholar
  17. 17.
    Yatsunenko T, Rey FE, Manary MJ, Trehan I, Dominguez-Bello MG, Contreras M, et al. Human gut microbiome viewed across age and geography. Nature. 2012;486(7402):222–7.CrossRefGoogle Scholar
  18. 18.
    He Z, Li P, Zhu J, Cui B, Xu L, Xiang J, et al. Multiple fresh fecal microbiota transplants induces and maintains clinical remission in Crohn’s disease complicated with inflammatory mass. Sci Rep. 2017;7(1):4753.CrossRefGoogle Scholar
  19. 19.
    Peng Z, Xiang J, He Z, Zhang T, Xu L, Cui B, et al. Colonic transendoscopic enteral tubing: a novel way of transplanting fecal microbiota. Endosc Int Open. 2016;4(6):E610–3.CrossRefGoogle Scholar
  20. 20.
    Yoshimura N, Watanabe M, Motoya S, Tominaga K, Matsuoka K, Iwakiri R, et al. Safety and efficacy of AJM300, an oral antagonist of alpha4 integrin, in induction therapy for patients with active ulcerative colitis. Gastroenterology. 2015;149(7):1775-83.e2.CrossRefGoogle Scholar
  21. 21.
    Baumgart DC, Bokemeyer B, Drabik A, Stallmach A, Schreiber S, Vedolizumab Germany C. Vedolizumab induction therapy for inflammatory bowel disease in clinical practice: a nationwide consecutive German cohort study. Aliment Pharmacol Ther. 2016;43(10):1090–102.CrossRefGoogle Scholar
  22. 22.
    Kelly CR, Kunde SS, Khoruts A. Guidance on preparing an investigational new drug application for fecal microbiota transplantation studies. Clin Gastroenterol. 2014;12(2):283–8.CrossRefGoogle Scholar
  23. 23.
    Cui B, Li P, Xu L, Peng Z, Xiang J, He Z, et al. Step-up fecal microbiota transplantation (FMT) strategy. Gut Microbes. 2016;7(4):323–8.CrossRefGoogle Scholar
  24. 24.
    Feuerstein JD, Nguyen GC, Kupfer SS, Falck-Ytter Y, Singh S; American Gastroenterological Association Institute Clinical Guidelines Committee. American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease. Gastroenterology. 2017;153(3):827–34.Google Scholar
  25. 25.
    Li P, Zhang T, Xiao Y, Tian L, Cui B, Ji G, et al. Timing for the second fecal microbiota transplantation to maintain the long-term benefit from the first treatment for Crohn’s disease. Appl Microbiol Biotechnol. 2019;103(1):349–60.CrossRefGoogle Scholar
  26. 26.
    EuroQol G. EuroQol: a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199–208.CrossRefGoogle Scholar
  27. 27.
    Zhang T, Xiang J, Cui B, He Z, Li P, Chen H, et al. Cost-effectiveness analysis of fecal microbiota transplantation for inflammatory bowel disease. Oncotarget. 2017;8(51):88894–903.Google Scholar
  28. 28.
    Tsuchiya A, Ikeda S, Ikegami N, Nishimura S, Sakai I, Fukuda T, et al. Estimating an EQ-5D population value set: the case of Japan. Health Econ. 2002;11(4):341–53.CrossRefGoogle Scholar
  29. 29.
    van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368(5):407–15.CrossRefGoogle Scholar
  30. 30.
    Kelly CR, Khoruts A, Staley C, Sadowsky MJ, Abd M, Alani M, et al. Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection: a randomized trial. Ann Intern Med. 2016;165(9):609–16.CrossRefGoogle Scholar
  31. 31.
    Uygun A, Ozturk K, Demirci H, Oger C, Avci IY, Turker T, et al. Fecal microbiota transplantation is a rescue treatment modality for refractory ulcerative colitis. Medicine. 2017;96(16):e6479.CrossRefGoogle Scholar
  32. 32.
    Youngster I, Sauk J, Pindar C, Wilson RG, Kaplan JL, Smith MB, et al. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Clin Infect Dis. 2014;58(11):1515–22.CrossRefGoogle Scholar
  33. 33.
    Cohen JI. Clinical practice: herpes zoster. N Engl J Med. 2013;369(3):255–63.CrossRefGoogle Scholar
  34. 34.
    Gupta G, Lautenbach E, Lewis JD. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4(12):1483–90.CrossRefGoogle Scholar
  35. 35.
    Costello SP, Hughes PA, Waters O, Bryant RV, Vincent AD, Blatchford P, et al. Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis: a randomized clinical trial. JAMA. 2019;321(2):156–64.CrossRefGoogle Scholar
  36. 36.
    Kump PK, Grochenig HP, Lackner S, Trajanoski S, Reicht G, Hoffmann KM, et al. Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitis. Inflamm Bowel Dis. 2013;19(10):2155–65.CrossRefGoogle Scholar
  37. 37.
    Ishikawa D, Sasaki T, Osada T, Kuwahara-Arai K, Haga K, Shibuya T, et al. Changes in intestinal microbiota following combination therapy with fecal microbial transplantation and antibiotics for ulcerative colitis. Inflamm Bowel Dis. 2017;23(1):116–25.CrossRefGoogle Scholar
  38. 38.
    Nishida A, Imaeda H, Ohno M, Inatomi O, Bamba S, Sugimoto M, et al. Efficacy and safety of single fecal microbiota transplantation for Japanese patients with mild to moderately active ulcerative colitis. J Gastroenterol. 2017;52(4):476–82.CrossRefGoogle Scholar
  39. 39.
    Fairhurst NG, Travis SPL. Why is it so difficult to evaluate faecal microbiota transplantation as a treatment for ulcerative colitis? Intest Res. 2018;16(2):209–15.CrossRefGoogle Scholar
  40. 40.
    Chu ND, Smith MB, Perrotta AR, Kassam Z, Alm EJ. Profiling living bacteria informs preparation of fecal microbiota transplantations. PloS One. 2017;12(1):e0170922.CrossRefGoogle Scholar
  41. 41.
    Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol. 2013;108(4):500–8.CrossRefGoogle Scholar
  42. 42.
    Narula N, Kassam Z, Yuan Y, Colombel JF, Ponsioen C, Reinisch W, et al. Systematic review and meta-analysis: fecal microbiota transplantation for treatment of active ulcerative colitis. Inflamm Bowel Dis. 2017;23(10):1702–9.CrossRefGoogle Scholar
  43. 43.
    Wang S, Xu M, Wang W, Cao X, Piao M, Khan S, et al. Systematic review: adverse events of fecal microbiota transplantation. PloS One. 2016;11(8):e0161174.CrossRefGoogle Scholar
  44. 44.
    Woodworth MH, Carpentieri C, Sitchenko KL, Kraft CS. Challenges in fecal donor selection and screening for fecal microbiota transplantation: a review. Gut Microbes. 2017;8(3):225–37.CrossRefGoogle Scholar
  45. 45.
    Angelberger S, Reinisch W, Makristathis A, Lichtenberger C, Dejaco C, Papay P, et al. Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. Am J Gastroenterol. 2013;108(10):1620–30.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Medical Center for Digestive Diseases, The Second Affiliated HospitalNanjing Medical UniversityNanjingChina
  2. 2.Department of Geriatrics, Sir Run Run HospitalNanjing Medical UniversityNanjingChina
  3. 3.Key Laboratory of Holistic Integrative EnterologyNanjing Medical UniversityNanjingChina

Personalised recommendations